Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NRC-2694 is an antagonist of the epidermal growth factor receptor (EGFR). It has anti-cancer and anti-proliferative properties.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 163.00 | |
5 mg | In stock | $ 328.00 | |
10 mg | In stock | $ 563.00 | |
25 mg | In stock | $ 891.00 | |
50 mg | In stock | $ 1,230.00 | |
100 mg | In stock | $ 1,670.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 365.00 |
Description | NRC-2694 is an antagonist of the epidermal growth factor receptor (EGFR). It has anti-cancer and anti-proliferative properties. |
In vitro | NRC-2694 (80 ng) induce comparable inhibition of EGFR expression. |
In vivo | NRC-2694 (10 mg/kg) regresses the tumor in mice. The maximum tolerated dose of NRC-2694 in male and female mice is 2000 mg/kg (p.o.), in toxicity studies . |
Molecular Weight | 418.49 |
Formula | C24H26N4O3 |
CAS No. | 936446-61-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (597.39 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
NRC-2694 936446-61-6 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR inhibit HER1 Epidermal growth factor receptor ErbB-1 Inhibitor NRC2694 NRC 2694 inhibitor